267 related articles for article (PubMed ID: 17719212)
1. On macroeconomic characteristics of pharmaceutical generics and the potential for manufacturing and consumption under fuzzy conditions.
Gascón F; de la Fuente D; Puente J; Lozano J
Artif Intell Med; 2007 Nov; 41(3):223-35. PubMed ID: 17719212
[TBL] [Abstract][Full Text] [Related]
2. Generics market in Greece: the pharmaceutical industry's beliefs.
Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
[TBL] [Abstract][Full Text] [Related]
3. International experiences of promoting generics use and its implications to China.
Sun J
J Evid Based Med; 2013 May; 6(2):74-80. PubMed ID: 23829799
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
5. The rise of the generic drug market and its implications for dermatology.
Bhosle M; Balkrishnan R; Dewan T; Yelverton CB; Feldman SR
J Dermatolog Treat; 2005; 16(5-6):295-8. PubMed ID: 16428148
[TBL] [Abstract][Full Text] [Related]
6. Generic medicines: Greek physicians' perceptions and prescribing practices.
Tsiantou V; Zavras D; Kousoulakou H; Geitona M; Kyriopoulos J
J Clin Pharm Ther; 2009 Oct; 34(5):547-54. PubMed ID: 19744010
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the pharmaceuticals market and its technological development in Turkey.
Kisa A
Int J Technol Assess Health Care; 2006; 22(4):537-42. PubMed ID: 16984690
[TBL] [Abstract][Full Text] [Related]
8. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
Kong Y
Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
[TBL] [Abstract][Full Text] [Related]
9. On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions.
Puente J; Gascon F; Ponte B; de la Fuente D
Artif Intell Med; 2019 Sep; 100():101703. PubMed ID: 31607342
[TBL] [Abstract][Full Text] [Related]
10. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
[TBL] [Abstract][Full Text] [Related]
11. A few specialty drug prices fall--all generics.
Manag Care; 2008 Dec; 17(12):46. PubMed ID: 19127766
[No Abstract] [Full Text] [Related]
12. Indian generics companies go on spending spree.
Jayaraman KS
Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583
[No Abstract] [Full Text] [Related]
13. Assessing water quality in rivers with fuzzy inference systems: a case study.
Ocampo-Duque W; Ferré-Huguet N; Domingo JL; Schuhmacher M
Environ Int; 2006 Aug; 32(6):733-42. PubMed ID: 16678900
[TBL] [Abstract][Full Text] [Related]
14. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
15. [Responsibilities and generic drugs].
Joly P
Bull Acad Natl Med; 1996 Feb; 180(2):463-73. PubMed ID: 8705384
[TBL] [Abstract][Full Text] [Related]
16. Price and welfare effects of a pharmaceutical substitution reform.
Granlund D
J Health Econ; 2010 Dec; 29(6):856-65. PubMed ID: 20832130
[TBL] [Abstract][Full Text] [Related]
17. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
Persson U; Ramsberg J
Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
[No Abstract] [Full Text] [Related]
18. [Analysis of generic drug supply in France].
Taboulet F; Haramburu F; Latry P
Rev Epidemiol Sante Publique; 2003 Sep; 51(4):415-25. PubMed ID: 13679734
[TBL] [Abstract][Full Text] [Related]
19. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
20. An aggregate fuzzy hazardous index for composite wastes.
Musee N; Lorenzen L; Aldrich C
J Hazard Mater; 2006 Sep; 137(2):723-33. PubMed ID: 16701941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
